Beta3_LVH: towards a treatment against heart failure
Enrolment ongoing on all sites!
February 27, 2017
Check out our conditions to be part of it!
New: counter of patients enrolled by site
October 21, 2016
It is new and it is next to your site in the "Our partners" tab. Check it out!
Perfect day from experience!
September 22, 2016
Day 1 (8.00 à 16.00):
8.00: Blood sampling + HbNO
8.30: EndoPAT+ Physical examination (BP,… )
13.45 : Exercise capacity
15.00 : ABPM on
Day 2 pm (15.30 à18.00) :
15.30: ABPM off
FPin at CUSL (Belgium)
September 26, 2016
Congratulations Dr Persu!
First patient enrolled at UMG-GOE
September 13, 2016
Congratulations to Prof. Rolf Wachter!!!
Thank you to the whole UMG-GOE's team!
Enrolment starts now!
April 29, 2016
The approval from competent authorities and ethic committee is received for:
Trial successfully passed the VHP procedure
February 2, 2016
VHP board accepted our protocol and we are now submitting to national Competent Authorities and Ethic Committee.
Protocol is finalised and wait for approval by ECRIN and DSMB
October 23, 2015
Partners have agreed to a version of the protocol. This version was finalised and edited by UNI-Leipzig before its approval by ECRIN and DSMB boards. Next step will be the submission to the VHP procedure.
Protocol in process
July 21, 2015
The writing of the protocol is performed by UNI-Leipzig. A draft version is currently prepared and will be ready for reviewing by the partners in september.
Launch of the Beta3 project
May 1, 2015
The Beta3_LVH project was submitted to the European commission on 19 August 2014 by Prof. Jean-Luc Balligand from the Université catholique de Louvain and officially started on the 1st may 2015. The kick off meeting gathering all european partners took place in Brussels on 10 June 2015.
Screening will start in March 2016
May 15, 2015
After the approval of competent authorities and ethic committees involves, the first patient in is expected for April 2016. Let's cross fingers!
If you think you might be elligible for taking part to this adventure, please contact your doctor who will inform you about this trial.